The central role of the intestinal microbiota in the progression and, equally, prevention of metabolic dysfunction is becoming abundantly apparent. The symbiotic relationship between intestinal microbiota and host ensures appropriate development of the metabolic system in humans. However, disturbances in composition and, in turn, functionality of the intestinal microbiota can disrupt gut barrier function, a trip switch for metabolic endotoxemia. This low-grade chronic inflammation, brought about by the influx of inflammatory bacterial fragments into circulation through a malfunctioning gut barrier, has considerable knock-on effects for host adiposity and insulin resistance. Conversely, recent evidence suggests that there are certain bacterial species that may interact with host metabolism through metabolite-mediated stimulation of enteric hormones and other systems outside of the gastrointestinal tract, such as the endocannabinoid system. When the abundance of these keystone species begins to decline, we see a collapse of the symbiosis, reflected in a deterioration of host metabolic health. This review will investigate the intricate axis between the microbiota and host metabolism, while also addressing the promising and novel field of probiotics as metabolic therapies.
Statistics from Altmetric.com
The Barker hypothesis, in which long-term metabolic outcomes are pre-programmed in the womb, has held centre stage for decades and may still remain at the heart of metabolic syndrome pathogenesis.1 ,2 However, the gut microbiota, also referred to as the hidden organ, or the organ within an organ, harbours tens of trillions of microorganisms residing in the human intestine, which are arguably as important to metabolic health as the very organs that support them. Over the last few decades, a myriad of original research publications and comprehensive review articles make it impossible to ignore the contribution of the gut microbiota towards health and disease. It is believed that the 1–2 kg of microorganisms in the human gut contain >150-fold more genes than the human genome itself, a concept that attracts researchers from gastroenterology, physiology and microbiology and one that demolishes the notion that the gut microbiota will ever again be described as a ‘forgotten organ’.
Although a very recent study has supported the possibility that the infant is first seeded with bacteria in utero from the maternal placental microbiome,3 the neonatal intestinal tract is rapidly colonised by bacteria from the mother and surrounding environment following birth. Of course, the delivery method—natural versus caesarean section—is a strong determinant of the first real microbial colonisers of the neonatal intestinal tract.4 Numerous publications have described clear differences in the gut microbiota composition between babies born via caesarean section versus natural birth5 ,6 and for breast-fed versus formula-fed babies.7–10 The gut microbiota continues to develop throughout childhood and adolescence and becomes more stable as it is generally assumed that the gut microbiota after around 3 years of age closely resembles that of an adult.11 ,12
The gastrointestinal (GI) tract of a healthy adult hosts around 102 microbial cells within the highly acidic environment of the stomach, into the duodenum and jejunum. The distal ileum contains around 107–108 microbial cells with the largest proportion of microbes finally residing in the colon, containing around 1011–1012 microbial cells. Difficulties arise in culturing the microbiota from this highly anaerobic environment, with only about 10–50% successfully culturable in the laboratory.13 It is only over the last few decades with the emergence of culture-independent sequencing technologies that we have gained such a vast insight into the compositional changes that exist between individuals in both healthy and diseased states. However, while compositional studies generate a large volume of data, they fail to provide direct information regarding the microbial viability or the functional potential of the populations present and so the knowledge is somewhat limited in these aspects.14 As such, much of our understanding of the role of the gut microbiota and individual microbes comes from the use of germfree animals, that is, those born and reared without exposure to microorganisms and microbial supplementation studies. Germfree animals have highlighted the importance of a gut microbiota in influencing many aspects of host biology, including metabolism,15 ,16 social development17 and immunity.18 For example, germfree animals show defects in both the development of the immune system and in immune responses. They show extensive defects in the development of gut-associated lymphoid tissue and cell-turnover rates of intestinal epithelial cells and have fewer and smaller Peyer's patches and mesenteric lymph nodes compared with animals housed under specific pathogen-free (SPF) conditions.19–22 It is now fully appreciated that host–microbe interactions can together co-metabolise dietary components to produce a large array of signalling molecules that develop ‘intelligent communication systems’ in the body with beneficial impacts on health. ‘Pharmabiotics’, that is, microbially produced bioactive metabolites, such as short-chain fatty acids, conjugated fatty acids, exopolysaccharides and neuroactive metabolites such as γ-aminobutyric acid (GABA) and serotonin, confer health benefits on the host.23–25 Thus, host–microbe interactions are crucial for optimum health.
While culture-independent analyses have broadened our understanding of gut microbiota composition and germfree studies have helped determine the role of gut microbes in health, it is now apparent that an individual's microbial signature is not only unique but could be a predetermining factor for disease risk. Recent literature has linked gut microbiota composition with almost every disease known to man, from GI diseases,26–29 to obesity,30–33 diabetes,34–38 cancer39–42 and even neurological and neurodegenerative disorders such as depression,43 ,44 autism,45–48 anxiety49 ,50 and Parkinson's disease.51 The demands for a clear link between the gut microbiota and disease have never been so high, and so advances in the development of methods used to analyse gene expression (metatranscriptomics), protein products (metaproteomics) and metabolic profiles (metabolomics) are proving crucial.14
This review will summarise the most relevant literature to date linking the gut microbiota with diet, obesity and diabetes and highlights some specific gut microbial compositional alterations that have been described as either potentially causal or protective towards metabolic disease.
Diet and obesity
Diet shapes the gut microbiota
Before addressing the involvement of the gut microbiota towards shaping obesity and associated metabolic disorders, it is appropriate to first briefly discuss some recent literature that describes diet as a dominant contributing factor to gut microbial composition. Indeed, dietary factors have a profound impact on altering the gut microbiota of animals52–58 and humans.31 ,59–61 This implies that health beneficial alterations to gut microbiota composition through dietary-related changes have rapidly become attractive mechanisms through which we may prevent or alleviate diseases appearing to arise from an altered microbial composition. Dietary patterns are associated with distinct combinations of bacteria in the intestine, also called enterotypes.62 Considering that the role of the gut microbiota is to ferment dietary substrates, complex diets can provide a range of growth-promoting and growth-inhibiting factors for specific phylotypes.63 The difficulty arises in deciphering which precise dietary constituents specifically promote the growth of health beneficial gut microbiota that maximise the production of pharmabiotics.23 Thus, the identification of dietary patterns or specific foods that increase bacterial diversity and promote the growth of beneficial bacteria that produce high levels of bioactive metabolites, is the ultimate research goal.
Western-style diets or various combinations of high fat (HF) diets, such as HF-high-sucrose and HF-low-plant-polysaccharide have profound effects on gut microbiota composition of animals and humans, often with conflicting results. Such HF-dietary-related gut microbial alterations often correlate with deleterious metabolic health effects.38 ,60 ,64 For example, one recent study in overweight and obese human subjects demonstrated the effects of three different dietary regimens on gut microbiota composition and health outcomes.65 They found that subjects consuming what was considered to be the least healthiest dietary regimen, characterised by the high consumption of confectionary and sugary drinks and the lowest consumption of fruits, yoghurt and water, had a significantly greater inflammatory profile compared with those consuming the healthiest dietary regimen, characterised by the lowest consumption of confectionary and sugary drinks and the highest consumption of fruits, yoghurts and soups.65 Interestingly, although the data did not highlight any significant changes to the seven gut microbial groups studied between the groups, the healthiest dietary regimen was associated with the highest microbial gene cluster or the highest microbial diversity/richness.65 This is indeed a significant finding as the importance of microbial diversity has previously been identified as a significant factor influenced by diet and exercise66 and which is also decreased during overweight and obese disease states.67 Fat type is also a strong determinant of inflammation and gut microbiota composition. Diets rich in saturated fat (lard) are associated with increased white adipose tissue (WAT) inflammation and metabolic disease, while diets rich in polyunsaturated fatty acids (fish oil) can counteract inflammation to promote a lean and metabolically healthy phenotype.68 ,69 In fact, mice fed fish oil have increased levels of taxa from the genera Lactobacillus and Akkermansia (discussed in more detail later) while mice fed lard have increased levels of taxa related to Bilophila.69 Bilophila wadsworthia has previously been shown to exacerbate colitis in genetically susceptible models.70 While previous studies have shown that microbial factors can directly contribute to WAT inflammation through Toll-like receptor (TLR) signalling,71 ,72 dietary and host factors are also strong TLR ligands and so whether gut microbial factors initiate TLR signalling with an effect on health is uncertain. Caesar et al proved that lard-induced WAT inflammation is mediated through gut microbial activation of TLR4. Trif−/− and Myd88−/− (adaptor proteins necessary for interpreting TLR signalling) mice were protected against lard-induced WAT inflammation and impaired insulin sensitivity. Furthermore, the authors discovered that serum lipopolysaccharide (LPS) levels were higher in mice fed lard compared with those fed fish oil, indicating that microbial factors are present in the periphery that affect WAT inflammation. The impact of gut microbial factors on lard-induced WAT inflammation was further elucidated by comparing the effects of lard and fish oil in conventionally raised and germfree mice. These results demonstrated an adiposity-independent link between the gut microbiota and WAT inflammation, which led the authors to conclude that microbially derived products act as mediators of inflammation through TLR signalling. This highlights the gut microbiota as independent factors aggravating inflammation following saturated fat feeding.69
The data of Clarke et al66 demonstrate the importance of dietary variation and protein consumption, coupled with exercise, towards shaping gut microbial composition. In this study, protein consumption positively correlated with high microbial diversity (22 distinct phyla) and athletes with a low body mass index had significantly higher levels of Akkermansia, previously shown to inversely correlate with obesity in both mice and humans.73 ,74 These results highlight the importance of dietary macronutrients and exercise on positively shaping the gut microbiota composition. Fascinating discoveries have been made from the recently development multi-taxon Insertion Sequencing (INSeq) method, which monitors the genetic factors that enable members of the gut microbial community to flourish within this niche.75 This approach can be used to understand the mechanisms (gene-level characterisation) that determine gut microbial fitness and perturbation through diet, disease and clinical treatment. Using this approach, Wu et al75 revealed a strain-specific and diet-specific fitness determinant (arbinoxylan utilisation locus) in Bacteroides cellulosilyticus WH2 that is critical for the organism's fitness during HF/simple-sugar feeding. What’s more, supplementation of drinking water with arbinoxylan (cereal-derived hemicellulose) in mice consuming this diet selectively increased the abundance of B. cellulosilyticus.75 Thus, by increasing our understanding of how host genotypic and phenotypic factors affect gut microbial niches, multi-taxon INSeq can provide gene-level characterisation of species and strain-specific fitness determinants that enable therapeutic interventions (eg, prebiotic supplementation) to manipulate gut microbial community structure and function in health.
It is, however, often very difficult to determine the extent by which dietary factors affect gut microbiota composition, aside from genetic factors. While we appreciate that the component members of the gut microbiota can be stable for years,76 the community structure or the relative abundances of each member is highly dynamic.77 To this end, Carmody et al78 described the role of host genetics in driving dietary-related alterations in gut microbiota composition. This study proved that diet is a predominant environmental factor over host genetics in shaping gut microbiota composition. This theory was based on previous studies whereby monozygotic twins failed to possess more similar gut microbiota profiles when compared with dizygotic twins at various ages from infancy to adulthood, suggesting that host genetic factors play a minor role in altering the human gut microbiota.30 ,79 The results showed that consumption of a HF-high-sugar diet reproducibly altered the gut microbiota in five inbred mouse strains, mice deficient for genes relevant to host–microbial interactions (MyD88−/−, NOD2−/−, ob/ob and Rag1−/−) and in >200 outbred strains.78 Thus, the study concluded that diet is a dominant environmental factor that alters the gut microbial community universally in the host, despite genetic variation. Furthermore, dietary-related gut microbial changes occurred within an average of 3.5 days and were reversible.78 Indeed, the interactions between host genetics and environmental conditions have recently been described as confounding factors in the development of metabolic syndrome. Ussar et al80 discovered that the phenotype of the 129SvEv/Tac (129T) mouse strain from Taconic Farms, usually susceptible to developing diet-induced obesity and enlarged livers on HF-diet but with normal insulin sensitivity and mild glucose intolerance, could be altered through environmental normalisation over at least three generations to become ‘metabolic syndrome resistant’, similar to the phenotype of the genetically related 129SvEv/ImJ (129J) strain from Jackson Laboratories. Environmental normalisation of the 129T strain remodelled the microbiota, and these changes correlated with a metabolic resistant phenotype.80 It must be noted that environmental normalisation of the C57Bl/6J and the 129J strains had no significant effect on metabolic phenotype, despite a changed gut microbiota.80 This study is crucial in describing the importance of dietary, genetic and microbial interactions on the development of metabolic syndrome.
If diet is a dominant environmental factor driving gut microbial changes, then Bolnick et al81 have demonstrated that these changes are sex dependent. Laboratory fish, laboratory mice and humans have all demonstrated sex-dependent, diet–microbiota associations. Interestingly, this means that diet affects gut microbiota differently in males and females. From a clinical perspective, if the intention is to take advantage of the dominant effect dietary factors have on shaping a more healthful gut microbiota, perhaps future therapies ought to be sex specific.
The gut microbiota shape obesity
On a global scale, projection estimations have predicted that the obesity epidemic rose from 400 million obese adults in 2005 to >700 million in 2015, a trend that is set to continue towards 2030.82 ,83 Characterised by an excess accumulation of body fat and a low-grade systemic inflammatory tone, behavioural patterns including dietary trends remain the underlying cause of this imbalance of energy input versus expenditure. Convenient, easily accessible, energy-dense foods and overnutrition represent major starting points altering lipid metabolism, systemic inflammation and the gut microbiota. Although studies highlighting the impact of dietary patterns and overnutrition on gut microbiota composition are plentiful, few decipher a clear link between the microbial changes observed and the mechanisms involved. In addition, the definition of this ‘microbial signature’ of obesity is ever changing, each new study describing conflicting compositional results to the last. Nonetheless, microbial intervention or the promotion/inhibition of the growth of certain species are attractive proposals for the future prevention of this obesity epidemic.
Turnbaugh et al84 performed one of the first studies that definitively linked the gut microbiota with weight gain, caused by an increase in the energy-harvesting capabilities of the ‘obese-microbiota’. The gut microbiome possesses glycoside hydrolase enzymes, not found in the human genome and that are crucially involved in hydrolysing and fermenting a wide variety of dietary polysaccharides that enhance host energy status.85 ,86 The microbially derived energy from these otherwise indigestible complex polysaccharides are in the form of short-chain fatty acids (SCFA) (acetate, butyrate and propionate, predominantly). SCFAs are crucial to host health and are the principal energy source for colonocytes as well as playing a key role in the prevention and treatment of metabolic and bowel disorders and certain types of cancer.87–91 Germfree mice develop less body fat than conventionally raised mice and germfree mice colonised with the gut microbiota of conventional mice, despite increasing their food intake and decreasing their metabolic rate.92 Furthermore, germfree mice colonised with an ‘obese-microbiota’ isolated from genetically obese ob/ob mice had a greater percentage increase in body fat than those colonised with a ‘lean-microbiota’, despite no significant differences in energy consumption or initial body fat/weight between the groups.84 In this setting, the germfree mouse model has provided invaluable insights into the link between gut microbiota and body fat accumulation in the host.
At the compositional level, obesity is associated with changes in abundance ratios of two of the most dominant phyla (constituting >90% of known phylogenetic categories), namely Firmicutes and Bacteroidetes (figure 1). However, while some studies have described increases in the proportion of Firmicutes to Bacteroidetes in the obese phenotype, compared with normal weight individuals30 and weight loss is said to reduce the Firmicutes to Bacteroidetes ratio in human subjects,31 these findings are not universal32 ,53 and so the usefulness of the Firmicutes:Bacteroidetes ratio as a compositional biomarker for obesity remains unclear.
The low-grade inflammatory state characteristic of obesity can be further exacerbated by microbiota-associated inflammatory processes (figure 1). Cani et al71 ,93 first described the concept of metabolic endotoxemia (ie, increased plasma LPS) in a series of experiments in mice. The first finding was that both fat feeding and a HF diet increased plasma LPS levels by two-fold and five-fold, respectively.71 It was also observed that subcutaneous infusions of LPS into mice increased insulin resistance and obesity similar to that seen after feeding the HF diet.71 This positive correlation between HF feeding, genetic obesity (ob/ob), type 2 diabetes (T2D) (db/db) and metabolic endotoxemia has since been confirmed in mice.94 ,95 Furthermore, probiotic,93 prebiotic96 and antibiotic94 therapies have improved metabolic inflammatory parameters in HF diet fed and ob/ob mice. In a healthy state, the translocation of LPS, through the intestinal epithelium, is restricted as it damages the integrity of the intestinal barrier. This gut barrier dysfunction observed in the obese state may represent an open door for microbes and microbial-derived LPS endotoxin to enter systemic circulation, increasing gut permeability94 ,97–99 and paracellular permeability by disrupting tight-junction proteins that link epithelial cells together (eg, claudin, occludin and zonula occludens).100 Mechanistically, increased gut permeability in obese mice may have been associated with an alteration in the expression, localisation and distribution of two tight-junction proteins (occludin and zonula occludens 1) in the small intestine.94 ,95 ,97 ,99 Thus, microbial-associated metabolic endotoxemia appears to represent one of the most important links between the gut microbiota, intestinal permeability and the low-grade inflammatory state linked with obesity.
Ridaura et al101 recently described a fascinating link between diet, gut microbial composition and obesity. Their cohort of female twin pairs, discordant for obesity, provided a unique opportunity to examine the interrelations between obesity, associated metabolic disorders, diet and the gut microbiota. Transplantation of human gut microbiota from each member of discordant twin pairs for obesity permitted the donors’ communities to be replicated in germfree mice, that is, transplantation of a human ‘obese-microbiota’ from one co-twin transmitted an increase in total body and fat mass, as well as other obesity-associated metabolic phenotypes with corresponding faecal bacterial cultures in germfree mice.101 Furthermore, cohousing mice transplanted with this human ‘obese-microbiota’ with mice transplanted with a human ‘lean-microbiota’ prevented the development of obesity.101 Invasion of specific members of the Bacteroidetes phylum from the transplanted mice with the ‘lean-microbiota’ to their ‘obese-microbiota’ littermates correlated with the prevention of obesity development.101 In addition, following consumption of a low-fat, high-fibre diet, the ‘obese-microbiota’ failed to colonise lean mice as efficiently as it had in mice consuming a HF, low-fibre diet when cohoused with mice transplanted with human ‘lean-microbiota’.101 The results of this study highlight both diet and environment as crucial factors involved in altering the microbiota to affect the metabolic phenotype in the host.
Compositional differences are evident in the obese relative to the lean state.67 With obese individuals harbouring lower bacterial richness and characterised by greater adiposity, with increased insulin resistance, dyslipidemia and higher rates of systemic inflammation (increased C reactive protein), when compared with high bacterial richness individuals.67 Importantly, the significant differences in bacterial richness and thus microbial communities/metabolic capabilities between obese and lean groups in this study were based on 46 genera. Bacteroides, Parabacteroides, Ruminococcus, Campylobacter, Dialister, Porphyromonas, Staphylococcus and Anaerostipes were more dominant in subjects of low bacterial richness with an obese phenotype, while Faecalibacterium, Bifidobacterium, Lactobacillus, Butyrivibrio, Alistipes, Akkermansia, Coprococcus and Methanobrevibacter were more prevalent in subjects with high bacterial richness and a lean phenotype.67 These compositional data permitted a closer look to be taken at the microbial metabolic capabilities of individuals with high and low bacterial richness. It was concluded from the vast amount of data that subjects with low bacterial richness and an obese phenotype had (1) a reduction in butyrate-producing bacteria (2), a reduction in hydrogen and methane production (3), an increase in mucus degradation and (4) an increase in the potential to manage oxidative stress.67 Thus, it appears that obese individuals have lower bacterial richness and harbour a microbiota that predisposes them to further inflammation.
It is clear that obesity is associated with an altered gut microbiota that worsens this debilitating disease. Diversity is key to increasing the metabolic capabilities of the gut microbiota in order to prevent worsening metabolic endotoxemia, mucus degradation and oxidative stress. In the vast gut microbial ecosystem, two residents have been the subject of extensive research over the last number of years due to their negative association with the obese phenotype. Intriguing data have supported an antiobese movement of these two species, so much so that alleviating obesity and associated metabolic disorders through increasing their abundances has become a real opportunity.
A. muciniphila is a mucin-degrading Gram-negative bacterium residing in the mucus layer of intestinal epithelial cells and that constitutes about 3–5% of the gut microbiota biomass in humans.102 Murine73 and human74 studies have demonstrated an inverse correlation between A. muciniphila and overweight, obesity and diabetes. Everard et al73 ,99 reported convincing data describing a potential protective function of A. muciniphila in murine models of obesity. They describe a comprehensive data set highlighting an inverse correlation between genetic and dietary models of obesity and gut concentrations of A. muciniphila.73 Furthermore, prebiotic supplementation with oligofructose (dietary fibre) dramatically increased the abundance of A. muciniphila in genetically obese mice99 and restored the decreased basal levels of A. muciniphila associated with obesity, improving metabolic function and endotoxemia.73 Such studies suggest that A. muciniphila plays a role in controlling fat storage, adipose tissue inflammation and glucose metabolism.
A recent ex vivo model based on mouse ileal organoids has provided some novel data linking the gut microbiota and the host.103 Lukovac et al103 reported that ileal organoid expression of fasting induced adipocyte factor, G-protein coupled receptor (Gpr)-43, histone deacetylases and peroxisome proliferator-activated receptor-γ were modulated by A. muciniphila and the SCFA, propionate.104 Thus, it is clear that A. muciniphila and its SCFA regulate transcription factors and genes involved in cell cycle control, lipolysis and satiety.103 Previously, the effect of A. muciniphila on cell survival, more specifically in cell death receptor signalling within ileal tissue, has also been described in vivo in germfree mice.105
Early life therapy in the non-obese diabetic (NOD) mouse model of diabetes with antibiotics increased the relative abundance of A. muciniphila with an improvement to the diabetic phenotype.106 In addition, Dubourg et al107 demonstrated a dramatic colonisation of the human gut microbiota by the phylum Verrucomicrobia following broad-spectrum antibiotic treatment. Interestingly, all Verrucomicrobia phylotypes were represented by A. muciniphila.107 This shift in gut microbial composition highlights the susceptibility of some bacterial populations following antibiotic therapy and the susceptibility of other more resistant microorganisms to thrive under antibiotic pressure.108 In a follow-up study, Caputo et al109 assembled the whole genomes of A. muciniphila isolated directly from the stool of the patients who partook in the previous study using a metagenomic approach.
Despite the confounding evidence suggesting the anti-inflammatory effects of A. muciniphila in obesity,73 diabetes106 and colitis,110 others have failed to demonstrate such health benefits. Higher abundances of A. muciniphila have been observed in healthy controls in some human gut microbiota studies.38 In addition, the Chinese MGWAS study reported that 337 of the 2176 A. muciniphila-related genes were more abundant in T2D patients compared with healthy controls.37 It has also been suggested that A. muciniphila could facilitate intestinal inflammation through mucin degradation as previously shown in Salmonella typhimurium-infected mice.111 Such conflicting results highlight the need for further studies to decipher the precise role of A. muciniphila in inflammatory-related diseases and to clarify previous discrepancies.
Faecalibacterium prausnitzii is also an abundant intestinal microbe comprising approximately 4% of the mainly luminal microbiota.105 Patients with inflammatory symptoms of inflammatory bowel disease (IBD), obesity and related metabolic dysfunctions harbour reduced abundances of F. prausnitzii.37 ,38 ,74 ,112–114 Some recent functional studies have described increased F. prausnitzii in overweight subjects who underwent a fasting programme over 1 week followed by supplementation of a probiotic formula for 6 weeks.114 Dietary supplementation with a type 3-resistant starch in the SATIN project altered the gut microbiota composition in overweight human subjects by enriching taxa involved in starch degradation (Ruminococcus bromii) and butyrate production (Eubacterium rectale) and increasing F. prausnitzii.115 This study describes the association between microbial fermentation of resistant starch and satiety.115 Furthermore, F. prausnitzii has shown protective effects in both acute112 and chronic116 inflammatory responses in chemically induced models of inflammation. Considering the low-grade inflammatory tone, symptomatic of IBD and often associated with obesity, Martin et al recently investigated the protective effects of F. prausnitzii in a preclinical murine model of colitis.117 Importantly, decreased intestinal permeability was a feature following F. prausnitzii supplementation in mice chemically subjected to chronic low-grade inflammation and gut dysfunction compared with controls.117 Results from this study prompted the authors to describe F. prausnitzii as a potential novel probiotic that can be successfully used in the treatment of gut dysfunction and inflammation. Although the authors propose that the protective effects of F. prausnitzii could at least be in part due to the enhancement of tight junction proteins in the epithelial cells, promoting barrier function, further studies are needed to determine the precise role of F. prausnitzii in obesity and inflammatory-related metabolic diseases.
The endocannabinoid system and obesity
The endocannabinoid (eCB) system has been proposed to be involved in the regulation of energy homeostasis, appetite118 and gut barrier function119 via the microbiota–gut–brain axis during obesity.120 The eCB system is composed mainly of the bioactive lipids anandamide (AEA; an N-arachidonoylethanolamine), 2-arachidonoylgycerol (2-AG) (synthesised locally in the GI tract), the proteins that regulate their production/degradation and the cannabinoid receptors CB1 and CB2, through which they signal. While both AEA and 2-AG are CB1 and CB2 ligands, CB1 is expressed mainly in the liver, pancreas, adipose tissue and the peripheral and central nervous systems.121 CB2 is expressed mainly in the immune cells, in addition to the brain, pancreas and adipose tissue.122 In short, CB1 activation reduces gastric motility while CB2 activation reduces an inflammatory response. Interestingly, obesity is associated with an increase in eCB system tone123 and an altered expression of CB1. For example, CB1 receptor knockout mice have upregulated eCB signalling in a diet-induced obese mouse model.124 Muccioli et al125 have shown in genetically obese and T2D mice that CB1 receptor antagonists decreased gut permeability. Furthermore, by altering gut microbiota composition through prebiotic feeding, colonic CB1 mRNA expression is reduced and antibiotic treatment also decreased the expression of the CB1 receptor in the colon.125 These results correlate with a reduction in colonic AEA (endogenous CB1 ligand), an increase in fatty acid amine hydrolase (the main enzyme in degradation of AEA) and reduced plasma LPS levels.125 This suggests that the gut microbiota indeed play a role in regulating obesity and obesity-associated metabolic endotoxemia through the eCB system.
The gut microbiota and type 1 diabetes
Unlike T2D, type 1 diabetes (T1D) is primarily caused by a genetic disposition to pancreatic β-cell autoimmunity,126 in which inflammatory T cells are acknowledged to play a central role.127 Among the genetic loci identified in T1D patients, it is specific human leucocyte antigen (HLA) genotypes that have the strongest identified genetic factor to date.128 ,129 However, twin and family studies have shown that only a fraction of genetically predisposed individuals will go on to develop T1D,130–132 and with the incidence of T1D increasing steadily by about 3–4% over the past few decades, particularly among young children in developed countries,133 environmental factors seemingly play a stronger role than once anticipated towards triggering this autoimmune response. The impact of environmental factors on the increasing incidence and decreasing age of diagnosis of children with lower-risk class II HLA genes have been described.134 Infant feeding practices, diet and viruses are all relevant environmental triggers shown to play a role in disease onset. Moreover, risk of T1D onset in childhood is higher in children delivered by caesarean section,135 where there is also an altered gut microbiota composition.4
Genetically induced, that is, the NOD mouse and the bio-breeding diabetes prone (BBDP)/diabetes-resistant (BBDR) and chemically induced, that is, streptozotocin (STZ) and alloxan-induced T1D animal models all describe convincing data linking an altered microbiota with disease. Wen et al136 previously described the importance of the gut microbiota and its interactions with the host innate immune system in modulating T1D onset. MyD88 is an adaptor for multiple innate immune receptors, including TLRs involved in microbial sensing. It is the MyD88 signalling pathway that is required for autoimmune diabetes development in NOD mice under SPF conditions.136 The knockout of MyD88 in NOD mice completely protects against T1D development.136 Furthermore, heterozygous MyD88−/− NOD mice, which normally develop robust diabetes, are protected from disease development when exposed from birth to the gut microbiota of a MyD88 knockout NOD donor.136 Thus, disease progression in the NOD mouse is partly driven by an exaggerated innate immune response to symbiotic microbiota and altering microbial composition can curtail this response and prevent disease. Exposure to bacterial antigens and infections has also been shown to decrease the risk of NOD mice developing T1D.137
Further evidence for the role of the gut microbiota in T1D arises from the studies of BBDP and BBDR rodents. Interestingly, treating BBDP mice with antibiotics decreased their risk of developing T1D.138 Focusing on the proportions of bacteria found in BBDP rats at disease onset, probiotic-like microbiota such as bifidobacteria and lactobacilli were lower while Bacteroides, Ruminococcus and Eubacterium were higher compared with BBDR rats.139 However, pre-T1D onset the gut microbiota of BBDP rats was significantly different to that of BBDR rats139 and so it is difficult to conclude from this study whether microbial alterations were causal or consequential of disease since changes were observed before and after disease onset. Recently, we described distinct microbial alterations in STZ-induced T1D rats over time.140 In this study, rats were injected with a single dose of the pancreatic β-cell toxin STZ and T1D was apparent following 1 week. Although this model was severe, given the lack of insulin therapy throughout the 5 weeks of disease, with blood glucose levels between 500 and 600 mg/dL in diabetic rats, it does provide a comprehensive account of the microbial alterations that occurred following disease onset and progression over time.140 Most notably, T1D onset was associated with a shift in the Bacteroidetes: Firmicutes ratio, while at the genus level increased proportions of lactic acid producing, Bifidobacterium and Lactobacillus were identified at the later stages of T1D progression. Coincidently, T1D increased caecal lactate levels and decreased caecal butyrate levels compared with healthy controls. It has been suggested that the imbalance of bacteria that produce SCFA can affect gut permeability and cause T1D. Brown et al35 have described the importance of butyrate in intestinal permeability during T1D. Heightened gut permeability has been demonstrated as one of the phenomena that precedes the clinical onset of T1D in both animal models of autoimmune diabetes as well as in patients with T1D and pre-diabetic individuals.141–145 It is the fate of lactate that is crucial in determining intestinal health as conversion to butyrate results in mucin synthesis146–149 and tighter junctions150 ,151 while conversion to other SCFA such as acetate and propionate does not induce mucin synthesis.35 In addition, butyrate contributes to colonic health through its anti-inflammatory properties152–154 and decreases bacterial transport across metabolically stressed epithelial cells,153 thus preventing the development of the so-called ‘leaky gut’. Furthermore, the STZ-induced T1D rats demonstrated a reduced microbial diversity after just 1 week of disease onset that did not recover over the duration of the trial.140 Previously described are the links between a reduced microbial diversity and obesity-associated metabolic diseases.67
The altered gut microbiota associated with T1D has also been reported in numerous human studies. A 4-matched case–control study in Finland reported that the gut microbiota differed between children who were healthy and those with autoimmune disorders.155 A higher level of Bacteroidetes relative to Firmicutes approximately 6 months after birth was observed in those who eventually developed T1D and suggested that this ratio of Bacteroidetes to Firmicutes increased over time in autoimmune cases, but declined in those who did not develop T1D.155 The authors concluded that the ratio of Bacteroidetes to Firmicutes could be an early diagnostic marker of pending autoimmunity problems. Such case–control studies have associated a higher Bacteroides abundance with autoimmunity, with increased Bacteroides ovatus and Bacteroides uniformis and decreased Bacteroides fragilis in T1D patients.34–36 ,155 Furthermore, butyrate producers such as Faecalibacterium and Roseburia and mucin degraders Prevotella and Akkermansia were all found in greater proportions in healthy controls compared with cases and have been described as protective against T1D.34–36 ,155 A recent German study, however, found no differences in the Bacteroides abundance between children who developed anti-islet cell autoimmunity and healthy controls between 6 months of age and 3 years.156 They did, however, observe an increase in the abundance of the phylum Verrucomicrobia, of which Akkermansia is the only known gut microbial member.105 ,156 Previously, Brown et al35 suggested that a gut microbiota abundant with butyrate producers, increases mucin production, increases tight junction assembly, and thus, increases epithelial cell integrity. Therefore, with increased mucin production, a favourable niche exists for mucin degraders such as A. muciniphila that could possibly be used as an indicator of gut integrity.35 A very recent study has extensively examined the gut microbiota composition and diversity of 33 infants genetically predisposed to T1D.157 The authors acknowledged the limitations of the study being that all children in their cohort carry T1D-predisposing HLA alleles and are restricted to the countries of Finland and Estonia; nonetheless, their results are extremely novel in linking the gut microbiota with disease.157 The study reported a 25% reduction in gut microbial diversity in T1D patients compared with seroconverters (those positive for at least two of the five autoantibodies analysed; insulin autoantibodies, glutamic acid decarboxylase antibodies, islet antigen-2 antibodies, zince transporter eight antibodies and islet cell antibodies) and non-converters. Importantly, this was associated with alterations to both phylogenetic microbial composition and metabolic pathways in T1D diagnosed children throughout the study period.157 In addition, these shifts occurred prior to disease onset but after seroconversion and were specific to T1D progressors but not seen in seroconverters without disease.157 Remarkably, this novel data set describes a gut microbial profile that precedes T1D development but that is not found in seroconverters without disease or non-converters. Such results highlight a unique opportunity to exploit gut microbial profiles in distinguishing between T1D progressors from non-progressors and so has major implications for the future treatment of disease, based on microbial profiles.
The gut microbiota and T2D
It is estimated that >80% of patients with T2D are overweight and increased body weight is now recognised as the greatest risk factor of T2D, aside from genetic and lifestyle factors. Numerous studies have focused on the relationship between obesity and the gut microbiota; however, with T2D now generally considered an attribute to obesity, observational studies linking glucose intolerance and insulin resistance associated with T2D with the gut microbiota are somewhat lacking. Once again, inflammatory pathways underscore the evolution of insulin resistance.158 Patients with metabolic syndrome and T2D exhibit a remarkable endotoxemia.159 ,160 Recent studies have suggested that LPS may be crucially involved in T2D-associated inflammation. Serino et al161 reported an increase in gut permeability and endotoxemia with a specific gut microbial profile in mice receiving a HF diet until they became diabetic. In line with this, Amar et al162 ,163 described the concept of ‘metabolic infection’ to define the contribution of the gut microbiota in the endotoxemia-associated inflammation coupled with insulin resistance in T2D. Blood levels of certain bacterial DNA (>85% derived from Proteobacteria) were found to be enhanced in pre-diabetes.163 Microbially derived endotoxin could, therefore, play a significant role in insulin resistance associated with T2D.
Qin et al37 were among the first authors to complete a significant metagenome-wide association study in T2D. High-throughput sequencing on a cohort of Chinese patients with T2D demonstrated some interesting correlations between the clinical data and gut microbial composition.37 While butyrate-producing bacteria (Clostridiales sp. SS3/4, E. rectale, F. prausnitzii, Roseburia intestinalis, among others) were enriched in healthy control subjects, patients with T2D exhibited an altered gut microbial profile, marked by decreased butyrate-producing bacteria such as R. intestinalis and F. prausnitzii.37 Interestingly, the T2D gut microbial profile was colonised by opportunistic pathogens such as Bacteroides caccae, various Clostridiales, Escherichia coli and the sulfate-reducing species Desulfovibrio.37 The functional capacity of the T2D gut microbial profile was linked with enrichment in the membrane transport of sugars, oxidative stress responses, branched chain amino acid transport, sulfate reduction and decreased butyrate biosynthesis.37 In total, >3% of the gut microbial genes differed between healthy controls and patients with T2D.37
In a follow-up study, Karlsson et al74 reported compositional changes linked with T2D in a Scandinavian cohort of postmenopausal women. The data presented in this cohort again revealed significant decreases in butyrate producers R. intestinalis and F. prausnitzii in T2D women compared with women with impaired glucose tolerance.74 Both cohorts also demonstrated increases in Lactobacillus species associated with T2D.37 ,74 As already discussed, butyrate plays a significant role in the maintenance of intestinal epithelial cell integrity with important functions in the prevention of ‘leaky gut’ associated with diabetes. Therefore, the role of SCFA, particularly butyrate and butyrate-producing bacteria, is crucial for health in obesity and diabetes. As studies in T2D consistently reveal that production of SCFAs, especially butyrate, is impaired, it is reasonable to assume that such mechanisms may contribute to the low-grade inflammation observed in such disorders.164
Although plentiful in compositional data, both Chinese and Scandinavian cohorts lacked data determining whether T2D-specific medication may or may not have influenced gut microbial profiles of patients or whether such medications could have ‘corrected’ the altered microbial ecosystem associated with T2D. Recent promising data described a role for metformin, one of the most widely prescribed T2D therapeutic agents, towards improving the gut microbial profile in T2D.165 Following 6 weeks of metformin treatment in HF-diet fed mice, both the glycaemic profile and microbial profile (29 genera) was altered, when compared with HF-fed controls.165 Interestingly, HF-fed mice treated with metformin showed higher abundances of the mucin-degrading bacterium Akkermansia that correlated with increased mucin-producing goblet cells.165 Furthermore, oral administration of A. muciniphila to HF-diet fed mice in the absence of metformin, significantly enhanced glucose tolerance and attenuated adipose tissue inflammation.165 This improvement in glucose tolerance associated with A. muciniphila had also previously been identified.73 The results of Shin et al were further confirmed a few months later by Lee and Ko,166 who demonstrated an increase in A. muciniphila following metformin treatment with a negative correlation between glycaemia and A. muciniphila abundance. In line with this, Zhang et al38 reported that the abundances of Verrucomicrobiaceae and A. muciniphila were significantly reduced in patients with pre-diabetes compared with healthy controls. Thus, A. muciniphila may contribute to the antidiabetic effect of metformin, suggesting that pharmacological manipulation of the gut microbiota in favour of Akkermansia may be a potential treatment for T2D. These studies describe attractive data sets that highlight the possibility of gut microbial manipulation to alleviate T2D and describes a new mechanism for the therapeutic effect of metformin in treating T2D.
Following on from this, one recent study dissected 784 available human gut genomes from the MetaHIT project, novel Danish MetaHIT genomes, cohorts of female Swedish patients with T2D and Chinese patients with T2D to demonstrate how metformin impacted on gut microbial profiles.167 For these 784 gut metagenomes, taxonomic and functional profiles were determined. Using the available data sets and controlling for metformin, the authors identified a unified signature of gut microbiome shifts in T2D, characterised by a depletion in butyrate-producing taxa.167 It was shown that gut microbial function was altered following metformin treatment such that intestinal lipid absorption and LPS-triggered local inflammation was reduced, providing a competitive advantage to Escherichia species, possibly triggering a positive feedback loop that contributed to the taxonomic changes.167 Akkermansia was also found at similar abundances in non-diabetic control and metformin-treated diabetic patients.167 Furthermore, functional analysis demonstrated significantly enhanced butyrate and propionate production potential in metformin-treated patients. This is of significance due to the potential of these SCFA to trigger intestinal gluconeogenesis.168 ,169 Thus, characterisation of a metformin-associated human gut microbiome highlighted novel microbial mechanisms that contribute to the beneficial effects of the drug on host metabolism and provided evidence for the importance of controlling for metformin treatment once reporting functional and compositional shifts in the human microbiome.
What’s more, microbial manipulation to treat insulin resistance has previously been described, whereby microbial faecal transplant from lean donors to male insulin-resistant subjects significantly improved peripheral insulin resistance associated with an altered small intestinal microbial composition.170
Probiotics as diabetic therapies
It is now well established that there is enormous potential for human metabolic health in the manipulation of the gut microbiome.171 We have already discussed the inverse relationship between gut microbiota diversity and diabetic state; however, it is likely that certain keystone microbial taxa, alongside diversity, may be at the centre of this association. Aside from diet, probiotic administration currently represents the most effective and safest means of selectively altering the gut microbiome, ultimately with the intention to improve host health.78 ,172
Probiotics for T1D
It is well established that the microbiome can have a central role in the progression of T1D.173 However, it also appears to be true that we can alter the microbiome to delay onset or manage T1D pathogenesis. Three main targets have emerged for probiotic therapy in T1D; reduction or redirection of autoimmunity, increased β-cell proliferation and decreased β-cell apoptosis (figure 2).
The redirection of T-cell differentiation towards Treg cells by probiotics, commensals and their metabolites has received some attention. A probiotic cocktail of three Lactobacillus plantarum strains was observed to significantly reduce inflammatory cytokines interferon (IFN)γ and tumour necrosis factor-α production, while increasing anti-inflammatory interleukin-10 production in a mouse model of autoimmunity.174 The zwitterionic polysaccharide of B. fragilis (PSA) has also been implicated in a similar mechanism of anti-inflammatory protection for autoimmune disease-induced mice.175 ,176 One study investigating the ability of two Lactobacillus spp. isolated from the GI tract of T1D-resistant mice found that administration of a Lactobacillus johnsonii delayed or prevented the onset of the disease in a BioBreeding model.177 The strain elicited this response by reducing host IFNγ and iNOS levels, while also increasing claudin expression.
Conversely, some members of the gut microbiota have been shown to accelerate T1D.178 Segmented filamentous bacteria (SFB) are a Gram-positive, strict anaerobe taxonomic lineage within the Clostridiaceae family, which occupy the GI tract.179 These SFB are found tightly associated with the intestinal wall and, as a result, interact with the host immune system causing considerable differentiation towards inflammatory TH17 cells in the small intestinal lamina propria.180 While this type of immunostimulation can be extremely important to the development of a healthy host immune system,181 this same action can exacerbate autoimmunity in others that are genetically susceptible to T1D.182 Just one probiotic strain has previously been described as displaying anti-SFB activity in an immunocompromised mouse model.183 However, the mechanistic features proposed by the authors are those common to many probiotics—direct pathogen exclusion, antimicrobial activity or indirect activity through host immunostimulation184 ,185—suggesting that SFB may be a potential target for probiotic therapy in T1D.
GABA is a metabolite produced from glutamate by the glutamate decarboxylase (GAD) pathway of many lactic acid bacteria,186 as a cellular response to acidic stress.187 In the host, GABA is produced by β-cells and acts as the main inhibitory neurotransmitter in the enteric and parasympathetic nervous systems, where it is involved in pain perception and stress.188 However, GABA has also been proposed as a potential therapy in T1D pathogenesis.189 ,190 GABA acts on β-cell receptors, GABAAR and GABABR, to increase insulin production and β-cell proliferation, while also reducing β-cell apoptosis.191 In addition, CD4+ T cells have also been shown to harbour GABAAR, allowing the amino acid to interact with the immune system to effectively inhibit the inflammatory process involved in the progression of T1D.192 ,193 While these studies have investigated the use of injected or parenteral delivery of pure GABA, none have applied GABA-producing probiotics to a T1D model. The research to date investigating the bioactivity of GABA-producing probiotics has been solely focused on the gut–brain axis.194 However, selected probiotics can produce physiologically relevant levels GABA in faecal fermentations186 and, as such, should be considered potential T1D therapies warranting further investigation. One such study recently conducted within our group investigated the potential of an efficient GABA-producing Lactobacillus brevis in modifying host metabolism (Marques et al, in press). Following 5 weeks of probiotic intervention, healthy rat serum insulin was increased by 70% when compared with controls, while all other metabolic parameters were not significantly altered.
An intriguing novel avenue that is currently being explored in probiotic research is the engineering of commensal bacteria that can deliver bioactive molecules capable of managing or correcting a disease state.195 Due to their safety and the association that probiotics have with host intestinal mucosa, this system has been of considerable interest for vaccine delivery (for review, see Wells and Mercenier186 ,196). Such treatments have been coined as synthetic signalling therapeutics.197 In a recent study, a recombinant probiotic Lactobacillus gasseri ATCC 33323 capable of secreting the inactive full length form of glucagon-like peptide-1 (GLP-1)(1-37) was designed.198 GLP-1 is a conserved mammalian peptide produced by neuroendocrine L-cells, which can lower postprandial glucose levels in T2D by stimulating insulin production and attenuating glucagon release.199 GLP-1 also acts systemically on the pancreas, liver, heart, stomach and brain, impacting on gastric emptying, satiety and lipid absorption and metabolism.200 ,201 As such, a plethora of drugs have been developed as GLP-1R agonists or blockers (gliptins) of DPP-4, the enzyme that cleaves active GLP-1 in circulation.202 Although GLP-1-based therapies have been entirely targeted towards the treatment of T2D, it has become clear that this full-length form of the peptide may have significant potential as a T1D therapy. GLP-1 was originally identified in its extended 1–37 form through cDNA cloning,203 although it was thought to have little bioactivity compared with the truncated GLP-1 (7–37 and 7–36), later discovered to be naturally produced by human β-cells.204 However, a recombinant GLP-1(1-37) producing E. coli has previously been shown to stimulate the production of 1 ng insulin per millilitre of media in Caco-2 cells.205 Furthermore, the peptide has also been implicated in the conversion of crypt-located small intestinal epithelial cells to insulin+ β-like-cells ex vivo.206 Following STZ-induction of T1D in mice, Duan et al demonstrated that twice daily administration of a high dose (1.6×1010 CFU/kg) of this recombinant GLP-1(1-37) producing probiotic for 90 days resulted in ∼30% restoration of insulin-production capabilities and significantly improved glucose metabolism. It was confirmed by immunofluorescent microscopy that this activity was through differentiation of intestinal crypt epithelial cells to β-like cells. Thus, GI tract-derived probiotics may serve as drug delivery or signalling systems, which could have downstream implications for diabetes.207 ,208
Probiotics for T2D
Much of the initial research around probiotics as T2D therapies has been through non-targeted approaches, assessing the ability of different lactobacilli and bifidobacteria to attenuate the effects of the disease state without any genuine molecular hypothesis prior to experimentation.209 ,210 More recent studies have progressed to implicating reduced inflammation, as a direct result of improved tight junction function preventing metabolic endotoxemia, as the source of the probiotic effect in diabetes therapy (figure 2).162 ,211 ,212 This attenuation of low-grade inflammation undoubtedly plays a central role in T2D therapy; however, the manner in which this is achieved by probiotic bacteria is complex. The most compelling theories of the T2D–microbiome interaction have come from the Delzenne and Cani group of the University of Louvain (for review, see Cani et al).162 ,204 ,206–214 The systematic research of this group has uncovered several metabolic targets for probiotic therapies, some of which we have previously discussed already.
The first and most thoroughly characterised targets for probiotic-mediated T2D therapy are the SCFA. SCFA—primarily acetate, butyrate and propionate—are thought to interact with the host enteroendocrine system by binding to GPR41 and GPR43.214 ,215 These GPCRs in turn upregulate the expression of gut hormone precursor peptide proglucagon,216 GLP-1,217 GLP-2,95 gastric inhibitory polypeptide (GIP) and peptide YY (PYY) levels,218 as well as adipocyte-derived leptin,219 while downregulating ghrelin.220 As mentioned previously, GLP-1-based therapies have demonstrated great efficacy in treating patients presenting T2D, as well as dyslipidemia. However, microbiota-mediated modulation of these other gut hormones also has significant implications for metabolic health, affecting gut permeability, satiety, gastric emptying and food intake.221 Most recently, SCFAs have also been shown to act upon a cAMP-dependent mechanism, increasing intestinal gluconeogenesis,168 which is thought to contribute to satiety.222 While some studies have reported contrasting effects, this is likely a result of the varying actions of specific SCFA. As we have discussed previously, it appears that butyrate may be of most significance in the correction of metabolic endotoxemia disease states through proliferation of colonic epithelial cells and tight junction function.151 The importance of butyrate-producing bacteria in T2D development has been demonstrated by a recent human faecal transplant study.170 This research implicates enteric butyrate-producing bacteria, such as R. intestinalis, Faecalibacterium spp. and Eubacterium hallii, as potential probiotics for the alleviation of metabolic endotoxemia-induced T2D.223 There is also evidence that more classical probiotics, such as the commercial probiotic cocktail VSL#3, can offer complete correction of weight gain and glucose intolerance associated with diet-induced T2D in mice.224 Moreover, a recent transcriptomics study in elderly patients demonstrated the ability of Lactobacillus rhamnosus GG to promote the relative expression of butyrate-producing Roseburia and Eubacterium genes within the metagenome.225 This could offer a more intriguing mechanism for the anti-inflammatory effects attributed to traditional probiotics in T2D therapy.
The second proposed target for T2D probiotic therapy is the eCB system, already discussed in relation to obesity.226 CB1 is involved in gut permeability and modulation of the gut microbiota appears to yield similar responses to CB1 antagonists, upregulating expression and correcting the localisation of intestinal epithelial tight junction proteins, occludin and zonula occludens1.227 Furthermore, supplementation with 2×108 CFU/day of live A. muciniphila increased ileum 2-AG and 2-palmitoylglycerol levels in mice fed a HF diet, which had the knock-on effect of reducing serum LPS content.73 The manner in which A. muciniphila alters eCB levels remains unclear, but the correlation is apparent and this may offer a mechanism of action for the beneficial metabolic effects attributed to the strain.
Finally, eCB-like lipids, such as N-oleoylethanolamine, 2-oleoylglycerol (2-OG) and linoleoylethanolamine have been shown to interact with GPR119, a receptor that stimulates the host enteroendocrine system.228 Live A. muciniphila administration has demonstrated potential in altering 2-OG in mice fed a HF diet, contributing to tight junction function and significantly improving glucose metabolism, through stimulation of intestinal L-cell GLP-2 and GLP-1 production, respectively.73 In addition, the aforementioned increase in 2-AG production has been shown to potentiate anti-inflammatory effects from 2-OG, which could have further implications for correction of T2D.229
Additionally, GABA has also demonstrated potential in the treatment of T2D ex vivo230 and in vivo231 through the same pathways targeted for T1D. The former study, in which human pancreatic islets were excised, demonstrated that the GABA signalling pathway was hindered in T2D compared with healthy controls.230 However, GABABR agonist CPG55845 proved capable of stimulating insulin release from islets of both T2D and healthy control islets. Interestingly, Tian et al231 found that GABA therapy in a diet-induced obese model of T2D improved fasting glucose, glucose tolerance and insulin sensitivity through action on peripheral GABAAR-expressing immune cells. The study found that this in turn promoted a CD4+Fox3+ Treg differentiation tone and, as a result, reduced T2D-associated inflammation. The potential for GABA-producing probiotics as T2D therapies certainly warrants preclinical investigation.
Limitations and risks of microbiome-mediated therapies
While this review has highlighted the major advances and promising outcomes of current microbiome-metabolism research, it is important to comment on several limitations and potential risks associated with the science. In terms of limitations, as is the case for all personalised medicines, what works for me may not work for you. That is to say that an individual's genetics, specific diet, drug intake and endogenous microbiota may greatly impact on the efficacy of certain microbiome-mediated therapies. Moreover, some interventions may not only be ineffective in combating an individual's disease state, they may even be an additional risk factor. Certain avant-garde bacterial therapy procedures have demonstrated great potential in combating grave diseases: for example, the use of faecal microbiota transplants (FMTs) in the treatment of Clostridium difficile infection. However, with such efficacy comes risk. There have been several anecdotal reports and a single case study reporting increased weight gain following FMT from overweight donors,232 mirroring preclinical outcomes. In addition, there has even been speculation that transplantation from a mentally unfit donor could induce the same phenotype in the recipient. Although it is unlikely that single or even multistrain bacterial therapies, which have undergone strenuous preclinical and clinical investigation, would transfer such deleterious attributes. However, it certainly warrants attention, and microbiome-mediated therapies such as FMT will require significant regulation in order to reduce safety risks and ensure whole system host health.
The obesity epidemic has become a thorn in the side of a 21st-century global health crisis. Modern sequencing technologies have demonstrated that we are more microbe than man, in fact we always were, but the vast data now available to prove this are unarguable. The relationship between microbe and man is symbiotic, but all good relationships need work. And so we must nurture and feed ourselves healthy by indirectly feeding our microbes healthy too. The compelling evidence described in this review suggests that diet and environment can shape gut microbial composition and, in turn, gut microbial composition can have direct effects on human health. The ultimate goal is to permanently switch off this microbiota-influenced ‘trip switch’ determining metabolic endotoxemia in the host. This may be ambitious right now, but it is clear that certain strains of bacteria (and the pharmabiotics they produce) can have very positive effects on host metabolic health. Although these effects may seem a small solution to this epidemic, the future development of probiotics as medicines to treat metabolic disease or indeed prevent their onset is a promising proposal. The data described in this review bring us ever closer to discovering an ‘antiobese microbiota’, one that could prevent this obesity epidemic from polluting future global health.
While the gut microbiota is unique and essential for development, its composition can be influenced by many factors including health status and environment.
‘Pharmabiotics’ are bioactive microbial metabolites that confer a health benefit to the host.
The gut microbiota are a modifiable target with the potential to progress or prevent the development of the metabolic syndrome.
Current research questions
Can we eat ourselves healthy by feeding specific gut microbes?
Is it possible to transplant a healthful ‘lean-microbiota’ to an obese host with the effect of alleviating symptoms of the metabolic syndrome?
Can specific strains of bacteria be used as future therapies against diabetes or could potential disease-provoking strains be knocked out of the gut microbial ecosystem?
Murphy EF, Cotter PD, Healy S, et al. Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut 2010;59:1635–42.
Ridaura VK, Faith JJ, Rey FE, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013;341:1241214.
Cani PD, Geurts L, Matamoros S, et al. Glucose metabolism: focus on gut microbiota, the endocannabinoid system and beyond. Diabetes Metab 2014;40:246–57.
Everard A, Belzer C, Geurts L, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA 2013;110:9066–71.
Tian J, Dang HN, Yong J, et al. Oral treatment with gamma-aminobutyric acid improves glucose tolerance and insulin sensitivity by inhibiting inflammation in high fat diet-fed mice. PLoS ONE 2011;6:e25338.
Self assessment questions
Please answer true or false to the below.
Metabolic endotoxemia is characterised by excess lipopolysaccharide in the blood.
The endocannabinoid system is comprised of an array of signalling peptides.
Akkermansia can improve host insulin resistance in mice.
The pharmabiotic γ-aminobutyric acid functions as an excitatory neurotransmitter in the central nervous system.
Prebiotics are live microorganisms that may offer a therapeutic means of managing metabolic health.
Contributors EP, PMR and CS wrote the manuscript. JFC, GFF, RPR and TGD made substantial contributions to the overall content of the manuscript, and all authors had responsibility for the final content.
Funding PMR is in receipt of a Teagasc Walsh Fellowship. This work is supported by the APC Microbiome Institute. The APC Microbiome Institute is a research centre funded by Science Foundation Ireland (SFI). This publication has emanated from research supported by a research grant from Science Foundation Ireland (SFI) under grant number SFI/12/RC/2273.
Competing interests None declared.
Provenance and peer review Commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.